FDA awards Pfizer's RSV vaccine candidate priority review status
![Photo: Johanna Geron/Reuters/Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/14671754/18wcvm/ALTERNATES/schema-16_9/20221202-155049-4-2919x1641ma.jpg)
Pfizer will benefit from shorter processing time at the US Food and Drug Administration (FDA) for its RSV vaccine after receiving priority review status from the agency.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
GSK's RSV vaccine candidate wins FDA priority review status
For subscribers